AcRetia.com
About AcRetia.com
Working with experts in glycosylation chemistry, Acretia has helped to launch Biousian Biosystems Inc (BBI). BBI uses its synthetic glycosylation chemistry platform (CarboSyn) to develop pharmacologically attractive peptides. Providing seed capital and Rx development support, Acretia hopes to see BBI's lead programs targeting the delta opioid receptor move toward clinical trials.
